Table 2

Baseline characteristics and clinical outcomes after 4 months of RA patients classified either by 1987 or 2010 criteria and of UA patients

RA 1987RA 2010UA
BaselineN=364N=479p ValueN=122p Value*
Age, years (mean, SD)53.5 (14)52 (13)0.0852 (16)0.90
Female, no. (%)256 (70)333 (70)0.874 (61)0.06
Symptom duration, weeks (median, IQR)17 (8–32)18 (9–34)0.2516 (8–28)0.14
RF positive, no. (%)254 (67)330 (69)0.595 (4)<0.001
ACPA positive, no. (%)228 (63)324 (68)0.154 (3)<0.001
ESR mm/h (median, IQR)29 (15–45)26 (12–41)0.0416 (9–38)0.01
CRP mg/l (median, IQR)13 (6–35.5)11 (5–28)0.04610 (4–24)0.25
DAS (mean, SD)3.50 (0.9)3.34 (0.9)0.022.70 (0.65)<0.001
Swollen joint count (median, IQR)8 (4–12)7 (3–11)0.023 (2–6)<0.001
Tender joint count (median, IQR)7 (5–11)7 (4–10)0.185 (3–8)<0.001
HAQ (mean, SD)1.26 (0.65)1.19 (0.67)0.111.03 (0.62)0.02
BMI (mean, SD)25.5 (4.1)25.9 (4.5)0.1825.8 (4.0)0.88
Total SHS (median, IQR)0 (0-1)0 (0–0.5)0.330 (0–0.4)0.98
Erosive, no. (%)49 (13)60 (13)0.6212 (9)0.46
Follow-up (4 months)
DAS (mean, SD)1.56 (0.89)1.52 (0.89)0.561.43 (0.85)0.30
HAQ (mean, SD)0.45 (0.51)0.44 (0.53)0.810.44 (0.51)0.96
Improvement DAS (mean, SD)1.93 (1.04)1.82 (1.04)0.111.26 (0.88)<0.001
Improvement HAQ (mean, SD)0.80 (0.64)0.74 (0.66)0.160.59 (0.61)0.03
Total SHS (median, IQR)0 (0–1)0 (0–0.5)0.370 (0–0)0.85
Erosive, no. (%)48 (13)64 (13)0.9811 (9)0.22
SHS progression (median, IQR)0 (0–0)0 (0–0)0.750 (0–0)0.93
Remission (DAS<1.6), no. (%)211 (58)291 (61)0.5279 (65)0.46
  • * p Value based on difference between RA2010 and UA2010.

  • ACPA, anticitrullinated protein antibodies; BMI, body mass index; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SHS, Sharp/van der Heijde scoring method; UA, undifferentiated arthritis.